Skip to main content
Erschienen in: Virchows Archiv 3/2012

01.03.2012 | Review and Perspectives

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

verfasst von: Jaime Prat

Erschienen in: Virchows Archiv | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies. Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types (high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)) that account for over 95% of cases. These types are essentially distinct diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during oncogenesis, response to chemotherapy, and prognosis. For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical. The five tumor types are morphologically diverse and resemble carcinomas of the uterus. Actually, recent investigations have demonstrated that a significant number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily. This review summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.
Literatur
1.
Zurück zum Zitat Prat J (2004) Pathology of the ovary. Saunders, Philadelphia Prat J (2004) Pathology of the ovary. Saunders, Philadelphia
2.
Zurück zum Zitat Lee KR, Tavassoli FA, Prat J et al (2003) Surface epithelial-stromal tumours (Ch 2: tumours of the ovary and peritoneum). In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 117–145 Lee KR, Tavassoli FA, Prat J et al (2003) Surface epithelial-stromal tumours (Ch 2: tumours of the ovary and peritoneum). In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 117–145
3.
Zurück zum Zitat Shvartsman HS, Sun CC, Bodurka CC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM (2007) Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105:625–629PubMedCrossRef Shvartsman HS, Sun CC, Bodurka CC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM (2007) Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105:625–629PubMedCrossRef
4.
Zurück zum Zitat Stewart BW, Kleihues P (2003). World Cancer Report (IARC Press) Stewart BW, Kleihues P (2003). World Cancer Report (IARC Press)
5.
Zurück zum Zitat Jass JR (2006) Colorectal cancer: a multipathway disease. Crit Rev Oncog 12:273–287PubMed Jass JR (2006) Colorectal cancer: a multipathway disease. Crit Rev Oncog 12:273–287PubMed
6.
Zurück zum Zitat Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40:1213–1223PubMedCrossRef Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40:1213–1223PubMedCrossRef
7.
Zurück zum Zitat Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRef Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRef
8.
Zurück zum Zitat du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329PubMedCrossRef du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329PubMedCrossRef
9.
Zurück zum Zitat Fountain J, Trimble E, Birrer MJ (2006) Summary and discussion of session recommendations. Gynecol Oncol 103:S23–S25PubMedCrossRef Fountain J, Trimble E, Birrer MJ (2006) Summary and discussion of session recommendations. Gynecol Oncol 103:S23–S25PubMedCrossRef
10.
Zurück zum Zitat Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232PubMedCrossRef Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232PubMedCrossRef
11.
Zurück zum Zitat Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRef Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRef
12.
Zurück zum Zitat Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456PubMedCrossRef Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456PubMedCrossRef
13.
Zurück zum Zitat Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH (2001) Tubal ligation and risk of ovarian cancer. Lancet 358:844PubMedCrossRef Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH (2001) Tubal ligation and risk of ovarian cancer. Lancet 358:844PubMedCrossRef
14.
Zurück zum Zitat Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236PubMedCrossRef Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236PubMedCrossRef
15.
Zurück zum Zitat Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169PubMedCrossRef Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169PubMedCrossRef
16.
Zurück zum Zitat Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35PubMedCrossRef Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35PubMedCrossRef
17.
Zurück zum Zitat Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168–173PubMedCrossRef Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168–173PubMedCrossRef
18.
Zurück zum Zitat Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27:1–9PubMedCrossRef Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27:1–9PubMedCrossRef
19.
Zurück zum Zitat Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMed Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMed
20.
Zurück zum Zitat Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMed Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMed
21.
Zurück zum Zitat Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, IeM S (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nat Cancer Inst 95:484–486PubMedCrossRef Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, IeM S (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nat Cancer Inst 95:484–486PubMedCrossRef
22.
Zurück zum Zitat Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, IeM S (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 29:218–224PubMedCrossRef Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, IeM S (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 29:218–224PubMedCrossRef
23.
Zurück zum Zitat Laury AR, Ning G, Quick CM, Nucci MR, Parast MM, McKeon FD, Xian W, Crum CP (2011) Fallopian tube correlates of serous borderline tumors. Am J Surg Pathol 35:1759–1765PubMedCrossRef Laury AR, Ning G, Quick CM, Nucci MR, Parast MM, McKeon FD, Xian W, Crum CP (2011) Fallopian tube correlates of serous borderline tumors. Am J Surg Pathol 35:1759–1765PubMedCrossRef
24.
Zurück zum Zitat Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih Ie M (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRef Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih Ie M (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedCrossRef
25.
Zurück zum Zitat Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRef Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRef
26.
Zurück zum Zitat Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251PubMedCrossRef Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251PubMedCrossRef
27.
Zurück zum Zitat Al-Hussaini M, Stockman A, Foster H, Mc Cluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44:109–105PubMedCrossRef Al-Hussaini M, Stockman A, Foster H, Mc Cluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44:109–105PubMedCrossRef
28.
Zurück zum Zitat Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33:14–21PubMedCrossRef Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33:14–21PubMedCrossRef
29.
Zurück zum Zitat Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R (2011) Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 123:5–12PubMedCrossRef Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R (2011) Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 123:5–12PubMedCrossRef
30.
Zurück zum Zitat Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRef Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706PubMedCrossRef
31.
Zurück zum Zitat Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4:461–487PubMedCrossRef Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4:461–487PubMedCrossRef
32.
Zurück zum Zitat Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94:61–67PubMedCrossRef Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94:61–67PubMedCrossRef
33.
Zurück zum Zitat Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Prat J, Harkes I, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564–569PubMedCrossRef Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Prat J, Harkes I, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564–569PubMedCrossRef
34.
Zurück zum Zitat Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803–808PubMedCrossRef Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803–808PubMedCrossRef
35.
Zurück zum Zitat Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R (2010) Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29:1103–1113PubMedCrossRef Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R (2010) Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29:1103–1113PubMedCrossRef
36.
Zurück zum Zitat Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132PubMedCrossRef Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132PubMedCrossRef
37.
Zurück zum Zitat Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J (2010) Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 5:e10358PubMedCrossRef Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J (2010) Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 5:e10358PubMedCrossRef
38.
Zurück zum Zitat Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM (2010) The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116:5261–5271PubMedCrossRef Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM (2010) The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 116:5261–5271PubMedCrossRef
39.
Zurück zum Zitat Espinosa I, Catasus L, Canet B, D’Angelo E, Muñoz J, Prat J (2011) Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 24:846–854PubMedCrossRef Espinosa I, Catasus L, Canet B, D’Angelo E, Muñoz J, Prat J (2011) Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 24:846–854PubMedCrossRef
40.
Zurück zum Zitat Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defectin BRCA mutant cells as a therapeutic strategy. Nature 434:917–921PubMedCrossRef Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defectin BRCA mutant cells as a therapeutic strategy. Nature 434:917–921PubMedCrossRef
41.
Zurück zum Zitat Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Exploiting the DNA repair defectin BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70:139–148PubMedCrossRef Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Exploiting the DNA repair defectin BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70:139–148PubMedCrossRef
42.
Zurück zum Zitat Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC (2006) Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361–368PubMedCrossRef Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC (2006) Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361–368PubMedCrossRef
43.
Zurück zum Zitat Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D, Silva EG (2007) Inter-observer and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1203–1208CrossRef Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D, Silva EG (2007) Inter-observer and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1203–1208CrossRef
44.
Zurück zum Zitat Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, IeM S (2009) Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedCrossRef Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, IeM S (2009) Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedCrossRef
45.
Zurück zum Zitat Jones S, Wang T-L, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih I-M (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420PubMedCrossRef Jones S, Wang T-L, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih I-M (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420PubMedCrossRef
46.
Zurück zum Zitat Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35:934–948PubMedCrossRef Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35:934–948PubMedCrossRef
47.
Zurück zum Zitat Sieben NL, Roemen GMJM, Oosting J, Fleuren GJ, van Engeland M, Prat J (2006) Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol 210:405–411PubMedCrossRef Sieben NL, Roemen GMJM, Oosting J, Fleuren GJ, van Engeland M, Prat J (2006) Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol 210:405–411PubMedCrossRef
48.
Zurück zum Zitat Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3–10PubMedCrossRef Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3–10PubMedCrossRef
49.
Zurück zum Zitat Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26:139–152PubMedCrossRef Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26:139–152PubMedCrossRef
50.
Zurück zum Zitat Lee KR, Scully RE (2000) Mucinous tumors of the ovary—A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxomaperitonei”. Am J Surg Pathol 24:1447–1464PubMedCrossRef Lee KR, Scully RE (2000) Mucinous tumors of the ovary—A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxomaperitonei”. Am J Surg Pathol 24:1447–1464PubMedCrossRef
51.
Zurück zum Zitat Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, Copeland L, Silva E, Gorstein F, Young RH (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35:910–917PubMedCrossRef Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, Copeland L, Silva E, Gorstein F, Young RH (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35:910–917PubMedCrossRef
52.
Zurück zum Zitat Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long term follow-up. Am J Surg Pathol 22:1449–1462PubMedCrossRef Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long term follow-up. Am J Surg Pathol 22:1449–1462PubMedCrossRef
53.
Zurück zum Zitat Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors. Atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRef Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors. Atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRef
54.
Zurück zum Zitat Provenza C, Young RH, Prat J (2008) Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcoma-like mural nodules. Am J Surg Pathol 32:383–389PubMedCrossRef Provenza C, Young RH, Prat J (2008) Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcoma-like mural nodules. Am J Surg Pathol 32:383–389PubMedCrossRef
55.
Zurück zum Zitat Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O’Brien PM (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94:904–91353PubMedCrossRef Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O’Brien PM (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94:904–91353PubMedCrossRef
56.
Zurück zum Zitat Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRef Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRef
57.
Zurück zum Zitat Park SY, Kim HS, Hong EK, Kim WH (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef Park SY, Kim HS, Hong EK, Kim WH (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef
58.
Zurück zum Zitat Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM (2006) Immunohistochemical expression ofCDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM (2006) Immunohistochemical expression ofCDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef
59.
Zurück zum Zitat Ji H, Isacson C, Seidman J, Kurman RJ, Ronnett BM (2002) Cytokeratins 7and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21:391–400PubMedCrossRef Ji H, Isacson C, Seidman J, Kurman RJ, Ronnett BM (2002) Cytokeratins 7and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21:391–400PubMedCrossRef
60.
Zurück zum Zitat Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ (2008) Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32:1835–1853PubMedCrossRef Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ (2008) Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32:1835–1853PubMedCrossRef
61.
Zurück zum Zitat Irving JA, Catasús L, Gallardo A, Bussaglia E, Romero M, Matias-Guiu X, Prat J (2005) Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36:605–619PubMedCrossRef Irving JA, Catasús L, Gallardo A, Bussaglia E, Romero M, Matias-Guiu X, Prat J (2005) Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36:605–619PubMedCrossRef
62.
Zurück zum Zitat Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell D (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208PubMedCrossRef Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell D (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208PubMedCrossRef
63.
Zurück zum Zitat Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60:238–244PubMedCrossRef Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60:238–244PubMedCrossRef
64.
Zurück zum Zitat Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712PubMed Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712PubMed
65.
Zurück zum Zitat Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63–70PubMedCrossRef Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63–70PubMedCrossRef
66.
Zurück zum Zitat Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543PubMedCrossRef Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543PubMedCrossRef
67.
Zurück zum Zitat Lemon B, Inouye C, King DS, Tjian R (2001) Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature 414:924–928PubMedCrossRef Lemon B, Inouye C, King DS, Tjian R (2001) Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature 414:924–928PubMedCrossRef
68.
Zurück zum Zitat Birrer MJ (2010) The origin of ovarian cancer—is it getting clearer? N Engl J Med 363:1574–1575PubMedCrossRef Birrer MJ (2010) The origin of ovarian cancer—is it getting clearer? N Engl J Med 363:1574–1575PubMedCrossRef
69.
Zurück zum Zitat Palacios J, Gamallo C (1998) Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58:1344–1347PubMed Palacios J, Gamallo C (1998) Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58:1344–1347PubMed
70.
Zurück zum Zitat Catasús L, Bussaglia E, Rodriguez I, Gallardo A, Pons C, Irving JA, Prat J (2004) Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35:1360–1368PubMedCrossRef Catasús L, Bussaglia E, Rodriguez I, Gallardo A, Pons C, Irving JA, Prat J (2004) Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35:1360–1368PubMedCrossRef
71.
Zurück zum Zitat Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A, Armas A (1999) Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship withbeta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155:527–536PubMedCrossRef Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A, Armas A (1999) Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship withbeta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155:527–536PubMedCrossRef
72.
Zurück zum Zitat Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRef Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRef
73.
Zurück zum Zitat Catasus L, Gallardo A, Cuatrecasas M, Prat J (2008) PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 21:131–139PubMed Catasus L, Gallardo A, Cuatrecasas M, Prat J (2008) PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 21:131–139PubMed
74.
Zurück zum Zitat Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRef Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRef
75.
Zurück zum Zitat Gras E, Catasus L, Argüelles R, Moreno-Bueno G, Palacios J, Gamallo C, Matias-Guiu X, Prat J (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92:2829–2836PubMedCrossRef Gras E, Catasus L, Argüelles R, Moreno-Bueno G, Palacios J, Gamallo C, Matias-Guiu X, Prat J (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92:2829–2836PubMedCrossRef
76.
Zurück zum Zitat Moreno-Bueno G, Gamallo C, Perez-Gallego L, Calvo de Mora J, Suarez A, Palacios J (2001) Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10:116–122PubMedCrossRef Moreno-Bueno G, Gamallo C, Perez-Gallego L, Calvo de Mora J, Suarez A, Palacios J (2001) Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10:116–122PubMedCrossRef
77.
Zurück zum Zitat Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum based chemotherapy. Cancer 88:2584–2589PubMedCrossRef Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum based chemotherapy. Cancer 88:2584–2589PubMedCrossRef
78.
Zurück zum Zitat Komiyama S, Aoki D, Tominaga E, Susumu N, Udagawa Y, Nozawa S (1999) Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol 72:342–346PubMedCrossRef Komiyama S, Aoki D, Tominaga E, Susumu N, Udagawa Y, Nozawa S (1999) Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol 72:342–346PubMedCrossRef
79.
Zurück zum Zitat Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17PubMedCrossRef Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17PubMedCrossRef
80.
Zurück zum Zitat Kato N, Sasou S, Motoyama T (2006) Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 19:83–89PubMedCrossRef Kato N, Sasou S, Motoyama T (2006) Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 19:83–89PubMedCrossRef
81.
Zurück zum Zitat Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H (2009) The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 19:471–479PubMedCrossRef Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H (2009) The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 19:471–479PubMedCrossRef
82.
Zurück zum Zitat Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I (2003) Upregulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83:861–870PubMed Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I (2003) Upregulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83:861–870PubMed
83.
Zurück zum Zitat Canet B, Pons C, Espinosa I, Prat J (2011) Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. Hum Pathol 42:833–839PubMedCrossRef Canet B, Pons C, Espinosa I, Prat J (2011) Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. Hum Pathol 42:833–839PubMedCrossRef
84.
Zurück zum Zitat Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287PubMedCrossRef Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287PubMedCrossRef
Metadaten
Titel
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
verfasst von
Jaime Prat
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 3/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-012-1203-5

Weitere Artikel der Ausgabe 3/2012

Virchows Archiv 3/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie